CAMBRIDGE, Mass.--(BUSINESS WIRE)--NormOxys, Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body’s ability to deliver oxygen to diseased tissues, announced today the appointment of David Clark, MD, as its first Chief Medical Officer. Dr. Clark will manage NormOxys’ clinical affairs, including the development of its lead product candidate, OXY111A, which is expected to enter clinical trials in the first quarter of 2010.
